Brief: EMA's PRAC Warns About Known Risk Of Aseptic Meningitis With Chikungunya Vaccine Ixchiq
13/03/2026 11:04
March 13 (Reuters) - EMAs PRAC: EMA: PRAC WARNS ABOUT KNOWN RISK OF ASEPTIC MENINGITIS WITH CHIKUNGUNYA VACCINE IXCHIQ EMA'S PRAC: RECOMMENDED UPDATE TO IXCHIQ’S PRODUCT INFORMATION TO REFLECT MOST RECENT EVIDENCE RELATED TO KNOWN RISK OF ASEPTIC MENINGITIS Further company coverage: VLS.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency